Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Orchard Therapeutics stock

Learn how to easily invest in Orchard Therapeutics stock.

Orchard Therapeutics plc is a biotechnology business based in the US. Orchard Therapeutics shares (ORTX) are listed on the NASDAQ and all prices are listed in US Dollars. Orchard Therapeutics employs 224 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Orchard Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ORTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Orchard Therapeutics stock price (NASDAQ: ORTX)

Use our graph to track the performance of ORTX stocks over time.

Orchard Therapeutics shares at a glance

Information last updated 2022-01-17.
Latest market close$0.99
52-week range$1.12 - $9.08
50-day moving average $1.40
200-day moving average $3.27
Wall St. target price$9.79
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.21

Buy Orchard Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Orchard Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Orchard Therapeutics price performance over time

Historical closes compared with the close of $0.9895 from 2022-01-25

1 week (2022-01-19) -5.76%
1 month (2021-12-23) -25.60%
3 months (2021-10-26) -47.65%
6 months (2021-07-26) -66.46%
1 year (2021-01-26) -83.43%
2 years (2020-01-24) -92.50%
3 years (2019-01-25) 12.05
5 years (2017-01-22) N/A

Orchard Therapeutics financials

Revenue TTM $1.2 million
Gross profit TTM $1.7 million
Return on assets TTM -26.91%
Return on equity TTM -63.28%
Profit margin 0%
Book value $1.93
Market capitalisation $155.6 million

TTM: trailing 12 months

Orchard Therapeutics share dividends

We're not expecting Orchard Therapeutics to pay a dividend over the next 12 months.

Orchard Therapeutics share price volatility

Over the last 12 months, Orchard Therapeutics's shares have ranged in value from as little as $1.12 up to $9.08. A popular way to gauge a stock's volatility is its "beta".

ORTX.US volatility(beta: 1.11)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orchard Therapeutics's is 1.1066. This would suggest that Orchard Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Orchard Therapeutics overview

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company has a strategic collaboration agreement with Pharming Group N. V.

Frequently asked questions

What percentage of Orchard Therapeutics is owned by insiders or institutions?
Currently 0.118% of Orchard Therapeutics shares are held by insiders and 59.667% by institutions.
How many people work for Orchard Therapeutics?
Latest data suggests 224 work at Orchard Therapeutics.
When does the fiscal year end for Orchard Therapeutics?
Orchard Therapeutics's fiscal year ends in December.
Where is Orchard Therapeutics based?
Orchard Therapeutics's address is: 108 Cannon Street, London, United Kingdom, EC4N 6EU
What is Orchard Therapeutics's ISIN number?
Orchard Therapeutics's international securities identification number is: US68570P1012
What is Orchard Therapeutics's CUSIP number?
Orchard Therapeutics's Committee on Uniform Securities Identification Procedures number is: 68570P101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site